<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002854</url>
  </required_header>
  <id_info>
    <org_study_id>94098</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-IRB-94098</secondary_id>
    <secondary_id>NCI-V96-1042</secondary_id>
    <secondary_id>CDR0000065102</secondary_id>
    <nct_id>NCT00002854</nct_id>
  </id_info>
  <brief_title>High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer</brief_title>
  <official_title>PHASE I PILOT STUDY OF SEQUENTIAL HIGH DOSE CYCLES OF CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE AND IFOSFAMIDE, CARBOPLATIN AND TAXOL WITH AUTOLOGOUS STEM CELL SUPPORT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give&#xD;
      higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus peripheral&#xD;
      stem cell transplantation in treating patients who have advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the feasibility of administering 2 courses of high dose chemotherapy consisting&#xD;
           of etoposide, cisplatin, and cyclophosphamide followed by ifosfamide, carboplatin, and&#xD;
           paclitaxel (IC-T), each administered with filgrastim (G-CSF) and autologous stem cell&#xD;
           support, to patients with advanced carcinomas.&#xD;
&#xD;
        -  Describe the toxicity of these high dose chemotherapy regimens.&#xD;
&#xD;
        -  Define the maximum tolerated dose of paclitaxel deliverable in this high dose regimen.&#xD;
&#xD;
        -  Describe the pharmacokinetics of escalating doses of paclitaxel given as a 24-hour&#xD;
           continuous infusion.&#xD;
&#xD;
        -  Determine the disposition of carboplatin administered in the IC-T regimen.&#xD;
&#xD;
      OUTLINE: At least 4 weeks prior to chemotherapy, patients undergo stem cell collection&#xD;
      following filgrastim (G-CSF) mobilization. Sufficient stem cells to support 2 courses of&#xD;
      chemotherapy are required. Autologous bone marrow is collected as an adjuvant if stem cell&#xD;
      harvest is inadequate.&#xD;
&#xD;
      Patients then receive high dose cisplatin, etoposide, and cyclophosphamide over 10 days,&#xD;
      followed the next day by infusion of one fourth of the allotted stem cells, with the&#xD;
      remaining allotment infused 2 days later. G-CSF is given for granulocyte support.&#xD;
&#xD;
      Beginning no sooner than 14 weeks from the start of the first course of chemotherapy, stable&#xD;
      and responding patients receive high dose paclitaxel, carboplatin, and ifosfamide over 5&#xD;
      days, followed 2 days later with one-fourth of the allotted stem cells, with the remaining&#xD;
      allotment infused the following day. G-CSF is given for granulocyte support. Groups of 3-6&#xD;
      patients are treated with escalating doses of paclitaxel until the maximum tolerated dose for&#xD;
      this regimen is determined.&#xD;
&#xD;
      Patients are followed monthly for 1 year, every 3 months for 1 year, then as needed at the&#xD;
      physician's discretion for at least 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Three to six patients will be entered at each dose of paclitaxel studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1994</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of two cycles of high dose chemotherapy with stem cell reinfusion</measure>
    <time_frame>30 days from start of course II of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity of two cycles of high dose chemothearpy and stem cell reinfusion</measure>
    <time_frame>30 days from start of course II of treatment</time_frame>
    <description>Toxicity graded according to the NCI Common Toxicity Criteria and amended for subjects undergoing transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of two cycles of high dose chemothearpy and stem cell reinfusion</measure>
    <time_frame>30 days from start of course II of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Sequential high dose chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Sequential high dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Sequential high dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Sequential high dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Sequential high dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <arm_group_label>Sequential high dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <arm_group_label>Sequential high dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesna</intervention_name>
    <arm_group_label>Sequential high dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Sequential high dose chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Sequential high dose chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced carcinomas of the following types:&#xD;
&#xD;
               -  Breast carcinoma that is ineligible for or patient has refused participation in a&#xD;
                  higher priority protocol in the following categories:&#xD;
&#xD;
                    -  Stage II disease with at least 10 involved lymph nodes and no evidence of&#xD;
                       disease (NED) following surgery&#xD;
&#xD;
                    -  Stage III disease rendered surgically NED with or without radiotherapy&#xD;
&#xD;
                    -  Stage IV disease following partial response (PR) or complete response (CR)&#xD;
                       to surgery, chemotherapy, or radiotherapy&#xD;
&#xD;
                         -  Prior high dose chemotherapy allowed at discretion of investigator&#xD;
&#xD;
                         -  No chemoresistant disease rendered surgically NED&#xD;
&#xD;
                    -  Locoregionally recurrent disease within 2 years of breast conservation with&#xD;
                       or without chemotherapy&#xD;
&#xD;
          -  Stage III/IV ovarian cancer&#xD;
&#xD;
               -  PR/CR following debulking surgery and/or chemotherapy&#xD;
&#xD;
               -  Ineligible for or refused participation in higher priority protocols&#xD;
&#xD;
          -  Primary soft tissue sarcoma with high-grade disease greater than 10 cm or that is&#xD;
             metastatic&#xD;
&#xD;
               -  Rendered surgically NED or achieved PR/CR on any chemotherapeutic or&#xD;
                  immunotherapeutic regimen&#xD;
&#xD;
               -  Ineligible for or refused participation in higher priority protocols&#xD;
&#xD;
          -  Malignant melanoma in the following categories:&#xD;
&#xD;
               -  Ulcerative primary tumor with any number of completely resected metastatic lymph&#xD;
                  nodes&#xD;
&#xD;
               -  Stage II disease with more than 4 involved nodes rendered NED&#xD;
&#xD;
               -  Stage III disease rendered surgically NED or achieved PR/CR on any&#xD;
                  chemotherapeutic or immunotherapeutic regimen&#xD;
&#xD;
          -  Osteosarcoma that is ineligible for or refused participation in higher priority&#xD;
             protocols&#xD;
&#xD;
               -  Resected primary with less than 50% tumor necrosis on pathologic review&#xD;
&#xD;
               -  Metastatic disease rendered surgically NED or PR/CR on any chemotherapeutic,&#xD;
                  radiotherapeutic, or immunotherapeutic regimen&#xD;
&#xD;
          -  The following diseases rendered surgically NED or that achieved PR/CR on any&#xD;
             chemotherapeutic, radiotherapeutic, or immunotherapeutic regimen also eligible:&#xD;
&#xD;
               -  Small cell bone carcinoma&#xD;
&#xD;
               -  Metastatic Ewing's sarcoma&#xD;
&#xD;
               -  Metastatic gastrointestinal malignancy&#xD;
&#xD;
               -  Recurrent Wilms' tumor&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
          -  No current histologically confirmed bone marrow metastases&#xD;
&#xD;
               -  Prior bone metastases with resolution at time of entry permitted&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Physiologic 18 to 55&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 80%-100%&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm3&#xD;
&#xD;
          -  Platelet count greater than 120,000/mm3&#xD;
&#xD;
          -  Hemoglobin greater than 10 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT less than 3 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.4 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 70 mL/min&#xD;
&#xD;
          -  No history of hemorrhagic cystitis&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Ejection fraction at least 55% by MUGA&#xD;
&#xD;
          -  No significant cardiac disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV1 greater than 2 L&#xD;
&#xD;
          -  pO2 (room air) greater than 70 mm Hg&#xD;
&#xD;
          -  pCO2 (room air) less than 42 mm Hg&#xD;
&#xD;
          -  DLCO greater than 60% of predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No potentially disabling psychosocial history&#xD;
&#xD;
          -  No organic or functional CNS dysfunction or other medical problem that would present&#xD;
             party at undue risk&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  No hearing loss greater than 40 decibels&#xD;
&#xD;
          -  No contraindication to the following procedures:&#xD;
&#xD;
               -  Collection by apheresis of up to 16 x 10 to the 8th mononuclear cells mobilized&#xD;
                  by G-CSF&#xD;
&#xD;
               -  Collection of autologous bone marrow, if needed&#xD;
&#xD;
          -  No second malignancy except:&#xD;
&#xD;
               -  Nonmelanomatous skin cancer&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Adequate contraception required of fertile patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 3 prior chemotherapy regimens (excluding adjuvant therapy)&#xD;
&#xD;
          -  No more than 200 mg per square meter of prior cisplatin&#xD;
&#xD;
          -  No more than 800 mg per square meter of prior carboplatin&#xD;
&#xD;
          -  No prior exposure to greater than 1,000 mg per square meter of &quot;24-hour paclitaxel&#xD;
             equivalents&quot; (using a 1:1.3 ratio between paclitaxel doses given by 24-hour infusion&#xD;
             and by 3-hour infusion)&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to more than 20% of bone marrow&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Somlo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 24, 2015</last_update_submitted>
  <last_update_submitted_qc>August 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>localized osteosarcoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV anal cancer</keyword>
  <keyword>recurrent anal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

